

FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6

ANTI-MUC18 ANTIBODY C3.19.1

Nucleotide Sequence of heavy chain variable region

5' -

CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGC
ACTGTCTCTGGTGGCTCCATCAGTAGTTACTACTGGAGCTGGATCCGGCAGCCCCCAGGGAAGGGA
CTGGAGTGGATTGGCTATATCTATTACACTTGGACCTCCAACCTACAACCCCTCCCTCAAGAGTCGC
GTCACCATATCAGTGGACACGTCCAAAAACAGTTCTCCCTGAGGCTGAGTTCTGTGACCGCTGCG
GACACGGCCGTTTATTACTGTGCGAGAGATCAGGGGCAGTGGTTACTACCCGATGCTTTTGATATC
TGGGGCCAAGGGACAATGGTCACCGTCTCTTCAG 3' (SEQ ID NO: 3)

Amino Acid Sequence of Heavy Chain Variable Region

QVQLQESGPGLVKPSSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYTWSNYPNPSLKSR
VTISVDTSKNQFSLRLSSVTAADTAVYYCARDQGQWLLPDAFDIWGQGTMTVTVSS (SEQ ID
NO: 1)

Nucleotide Sequence of light chain variable region

5' -

GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCC
TGCAGGTCTAGTCAGAGCCTCCTGCGTAGTAATGGATACAACTATTTGGATTGGTACCTGCAGAAG
CCAGGACAGTCTCCACATCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGG
TTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTT
GGGGTTTATTACTGCATGCAAGCTCAACAAAGTCCGATCACCTTCGGCCAAGGGACACGACTGGAG
ATTAAAC 3' (SEQ ID NO: 4)

Amino Acid Sequence of Light Chain Variable Region

DIVMTQSPLSLPVTPGEPASISCRSSQSLLRNNGYNYLDWYLQKPGQSPHLLIYLGSNRASGVPDR
FSGSGSGTDFTLKISRVEAEDVGVYYCMQAQQSPITFGQGRLEIK (SEQ ID NO: 2)

FIGURE 7

ANTI-MUC18 ANTIBODY C6.11.13

Nucleotide Sequence of heavy chain variable region

5' -
CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGC
ACTGTCTCTGGTGGCTCCATCAGCAGTGGTACTTACCACTGGAGCTGGATCCGCCAGCACCCAGGG
AAGGGCCTGGAGTGGATTGGGTACATCTATTACAGTGGGAGCACCTACTACAACCCGTCCCTCAAG
AGTCGAGTTACCATATCAGTAGACACGTCTAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACT
GCCGCGGACACGGCCGTGTATTACTGTGCGAGAGGGGGAGATGGCTACAAGTACTGGGGCCAGGGA
ACCCTGGTCACCGTCTCCTCAG-3' (SEQ ID NO: 7)

Amino Acid Sequence of Heavy Chain Variable Region

QVQLQESGPGLVKPSQTLSTCTVSGGISSTYHWSWIRQHPGKGLEWIGYIYSGSTYYNPSLK
SRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGDGYKYWGQGLTVTVSS (SEQ ID NO:
5)

Nucleotide Sequence of light chain variable region

5'
GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCC
TGCAGGGCCAGTCAGAGTGTTAGCAACAACCTTAGCCTGGTATCAGCAGAAACCTGGCCAGGCTCCC
AGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCAAGTGGCAGTGGG
TCTGGGACAGAGTTCACCTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGT
CAGCAGTATAATAACTGGCCTCGGACGTTTCGGCCAAGGGACCAAGGTGGAAATCAAAC 3'
(SEQ ID NO: 8)

Amino Acid Sequence of Light Chain Variable Region

EIVMTQSPATLSVSPGERATLSCRASQSVSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSG
SGTEFTLTISLQSEDFAVYYCQQYNNWPRTFGQGTKVEIK (SEQ ID NO: 6)

FIGURE 8

ANTI-MUC18 ANTIBODY C3.10

Nucleotide Sequence of heavy chain variable region

```
1 CAGGTGCAGC TGCAGGAGTC GGGCCCAGGA CTGGTGAAGC CTTCGGAGAC CCTGTCCCTC
61 ACCTGCACTG TCTCTGGTGG CTCCATCAGT AGTTACTACT GGAGCTGGAT CCGGCAGCCC
121 CCAGGGAAGG GACTGGAGTG GATTGGCTAT ATCTATTACA CTTGGACCAC CAACTACAAC
181 CCCTCCCTCA AGAGTCGCGT CACCATATCA GTGGACACGT CCAAGAACCA GTTCTCCCTG
241 AGGCTGAGCT CTGTGACCGC TCGGACACG GCCCTTTATT ACTGTGCGAG AGATCAGGGG
301 CAGTGGTTAC TACCCGATGC TTTTGATATC TGGGGCCAAG GGACAATGGT CACCGTCTCT
361 TCAG (SEQ ID NO: 11)
```

Amino Acid Sequence of Heavy Chain Variable Region

```
1 QVQLQESGPG LVKPSETLSL TCTVSGGSIS SYYWSWIRQP PGKGLEWIGY IYYTWTNIN
61 PSLKSRVTIS VDTSKNQFSL RLSSVTAADT ALYYCARDQG QWLLPDAFDI WQGTMTVTS
121 S (SEQ ID NO: 9)
```

Nucleotide Sequence of light chain variable region

```
1 GACATCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CAGAGTCACC
61 ATCACTTGCC GGGCAAGTCA GAGCATTAGC AACTATTTAA ATTGGTATCA GCAGAAACCA
121 GGAAAAGCCC CTAAGCTCCT GATCTATGGT GCATCCAGTT TGCAAAGTGG GGTCCCATCA
181 AGGTTCACTG GCAGTGGATC TGGGACAGAT TTTACTCTCA CCATCAGCAG TCTGCAACCT
241 GAAGATTTTG CAACCTACTA CTGTCGACAG AGTTACAGTA CCCCTCCGGA GTGCAGTTTT
301 GGCCAGGGGA CCAAGCTGGA GATCAAAC (SEQ ID NO: 12)
```

Amino Acid Sequence of Light Chain Variable Region

```
1 DIQMTQSPSS LSASVGDRVT ITCRASQSIG NYLNWYQQKP GKAPKLLIYG ASSLQSGVPS
61 RFSGSGSGTD FTLTISSLQP EDFATYYCRQ SYSTPPECSF GQGTKLEIK (SEQ ID NO:
10)
```


FIGURE 9

ANTI-MUC18 ANTIBODY C3.22

Nucleotide Sequence of heavy chain variable region

```
1 CAGGTGCAGC TGCAGGAGTC GGGCCCAGGA CTGGTGAAGC CTTACAGAC CCTGTCCCTC
61 ACCTGCACTG TCTCTGGTGG CTCCATCAGC AGTGGTGGTT ACTACTGGAC TTGGATCCGC
121 CAGCACCCAG GGAAGGGCCT GGAGTGGATT GGGTTCATCT ATTACAGTGG GAGCACCTAC
181 TACAACCCGT CCCTCAAGAG TCGAGTTACC ATATCAGTAG ACACGTCTAA GAACCAGTTC
241 TCCCTGAAGC TGAGCTCTGT GACTGCCGCG GACACGGCCG TGTATTACTG TGCGAGAGAG
301 GGAGATGGCT TTGACTACTG GGGCCAGGGA ACCCTGGTCA CCGTCTCCTC AG (SEQ ID
NO: 15)
```

Amino Acid Sequence of Heavy Chain Variable Region

```
1 QVQLQESGPG LVKPSQTLST TCTVSGGSIS SGGYYWTWIR QHPGKGLEWI GFIIYSGSTY
61 YNPSLKSRVT ISVDTSKNQF SLKLSSVTAA DTAVYYCARE GDGFDYWGQG TLVTVSS (SEQ
ID NO: 13)
```

Nucleotide Sequence of light chain variable region

```
1 GACATCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CAGAGTCACC
61 ATCACTTGCC GGGCAAGTCA GGGCATTAGA AATGATTTAG GCTGGTATCA GCAGAAACCA
121 GGGAAAGCCC CTAAGCGCCT GATCTATGCT GCATCCAGTT TGCAAAGTGG GGTCCCATCA
181 AGGTTACGCG GCAGTGGATC TGGGACAGAA TTCACTCTCA CAATCAGCAG CCTGCAGCCT
241 GAAGATTTTG CAACTTATTA CTGTCTACAG CATAATAGTT ACCCGCTCAC TTTCGGCGGA
301 GGGACCAAGG TGGAGATCAA AC (SEQ ID NO: 16)
```

Amino Acid Sequence of Light Chain Variable Region

```
1 DIQMTQSPSS LSASVGDRVIT ITCRASQGIR NDLGWYQQKP GKAPKRLIYA ASSLQSGVPS
61 RFSGSGSGTE FTLTISSLQP EDFATYYCLQ HNSYPLTFGG GTKVEIK (SEQ ID NO: 14)
```

FIGURE 10

ANTI-MUC18 ANTIBODY C3.27

Nucleotide Sequence of heavy chain variable region

1 CAGGTGCAGC TGCAGGAGTC GGGCCCAGGA CTGGTGAAGC CTTCGGAGAC CCTGTCCCTC
61 ACCTGCACTG TCTCTGGTGG CTCCATCAGT AGTTACTACT GGAGCTGGAT CCGGCAGCCC
121 CCAGGGAAGG GACTGGAGTG GATTGGCTAT ATCTATTACA CTTGGACCTC CAACTACAAC
181 CCCTCCCTCA AGAGTCGCGT CACCATATCA GTGGACACGT CCAAGAACCA GTTCTCCCTG
241 AGGCTGAGTT CTGTGACCGC TGGCGACACG GCCGTTTACT ACTGTGCGAG AGATCAGGGG
301 CAGTGGTTAC TACCCGATGC TTTTGATATC TGGGGCCAAG GGACAATGGT CACCGTCTCT
361 TCAG (SEQ ID NO: 19)

Amino Acid Sequence of Heavy Chain Variable Region

1 QVQLQESGPG LVKPSSETLSL TCTVSGGSIS SYIWSWIRQP PGKGLEWIGY IYYTWTSNYN
61 PSLKSRVTIS VDTSKNQFSL RLSSVTAADT AVYYCARDQG QWLLPDAFDI WGQGTMTVTS
121 S (SEQ ID NO: 17)

Nucleotide Sequence of light chain variable region

1 GACATCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CAGAGTCACC
61 ATCACTTGCC GGGCAAGTCA GGGCATTAGA AATGATTTAG GCTGGTATCA GCAGAAACCA
121 GGGAAAGCCC CTAAGCGCCT GATCTATGCT GCATCCAGTT TGCAAAGTGG GGTCCCATCA
181 AGGTTTCAGCG GCAGTGGATC TGGGACAGAG TTTACTCTCA CAATCAGCAG CCTGCAGCCT
241 GAAGATTTTG CAACTTATTA CTGTCTACAG CATAATAGTT ACCCGTGGAC GTTCGGCCAA
301 GGGACCAAGG TGGAAATCAA AC (SEQ ID NO: 20)

Amino Acid Sequence of Light Chain Variable Region

1 DIQMTQSPSS LSASVGDRTV ITCRASQGIR NDLGWYQQKP GKAPKRLIYA ASSLQSGVPS
61 RFSGSGSGTE FTLTISSLQP EDFATYYCLQ HNSYPWTFGQ GTKVEIK (SEQ ID NO: 18)

FIGURE 11

ANTI-MUC18 ANTIBODY C3.45

Nucleotide Sequence of heavy chain variable region

```
1 CAGG TTCAGC TGGTGCAGTC GGGAGCTGAG GTGAAGAAGC CTGGGGCCTC AGTGAAGGTC
61 TCCTGCAAGG CTTCTGGTTA CACCTTTTTT AGCTATGGTT TCAGCTGGGT GCGACAGGCC
121 CCTGGACAAG GGCTTGAGTG GCTGGGATGG ATCAGCGCTT ACAATGGTAA CACAAACTAT
181 GCACAGAAGC TCCAGGGCAG AGTCACCATG ACCACAGACA CTTCACGAG CACAGCCTAC
241 ATGGAGCTGA GGAGCCTGAG ATCTGACGAC ACGGCCGTGT ATTACTGTGC GAGAGAAACT
301 AAGGTTCTGGG GAGTCCACTA CTACGGTATG GACGTCTGGG GCCAAGGGAC CACGGTCACC
361 GTCTCCTCAG (SEQ ID NO: 23)
```

Amino Acid Sequence of Heavy Chain Variable Region

```
1 QVQLVQSGAE VKKPGASVKV SCKASGYTFF SYGFSWVRQA PGQGLEWLGW ISAYNGNTNY
61 AQKLQGRVTM TTDSTSTAY MELRSLRSDD TAVYYCARET KVRGVHYYGM DVWGQGTIVT
121 VSS (SEQ ID NO: 21)
```

Nucleotide Sequence of light chain variable region

```
1 DIVMTQSPDS LAVSLGERAT IICKSSQSIL YSSNNKNYLG WYQQKPGQPP KLLIYWASTR
61 ESGVPARFSG SGSGTDFTLT INSLQAEDVA VYYCQYYST PRSFGQGTMV EIK (SEQ ID
NO: 24)
```

Amino Acid Sequence of Light Chain Variable Region

```
1 GACATCGTGA TGACCCAGTC TCCAGACTCC CTGGCTGTGT CTCTGGGCGA GAGGGCCACC
61 ATCATCTGCA AGTCCAGCCA GAGTATTTTA TACAGCTCCA ACAATAAGAA CTACTTAGGT
121 TGGTACCAGC AGAAACCAGG ACAGCCTCCT AAGCTGCTCA TTTACTGGGC ATCTACCCGG
181 GAATCCGGGG TCCCTGCCCC ATTCAAGTGGC AGCGGGTCTG GGACAGATTT CACTCTCACC
241 ATCAACAGCC TGCAGGCTGA AGATGTGGCA GTTTATTACT GTCAGCAATA TTATAGTACT
301 CCTCGGTCGT TCGGCCAAGG GACCATGGTG GAAATCAAAC (SEQ ID NO: 22)
```

FIGURE 12

ANTI-MUC18 ANTIBODY C3.65

Nucleotide Sequence of heavy chain variable region

```
1 CAGGTGCAGC TGCAGGAGTC GGGCCCAGGA CTGGTGAAGC CTTCACAGAC CCTGTCCCTC
61 ACCTGCACTG TCTCTGGTGG CTCCATCAAC AGTGGTGGTT GCTACTGGAG CTGGATCCGC
121 CAGCACCCAG GGAAGGGCCT GGAGTGGATT GGGTACATCT ATTCCAGTGG GAGCACCTAC
181 TACAACCCGT CCCTCAAGAG TCGAATTACC TTATCAGTAG ACACGTCTAA GAACCAGTTC
241 TCCCTGAAGC TGAAGTCTAT GACTGCCGCG GACACGGCCG TGTATTACTG TGCGAGAGAT
301 CGGGAAACAG CTGGTTTTGA CTACTGGGGC CAGGGAACCC TGGTCACCGT CTCCTCAG (SEQ
ID NO: 27)
```

Amino Acid Sequence of Heavy Chain Variable Region

```
1 QVQLQESGPG LVKPSQTLST TCTVSGGSIN SGGCYWSWIR QHPGKGLEWI GYIYSSGSTY
61 YNPSLKSRIT LSVDTSKNQF SLKLNSMTAA DTA VYYCARD RETAGFDYWG QGTLVTVSS
(SEQ ID NO: 25)
```

Nucleotide Sequence of light chain variable region

```
1 GACATCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CAGAGTCACC
61 ATCACTTGCC AGGCGAGTCA GGACATTAAC AACTATTTAA ATTGGTATCA GCAGAAACCA
121 GGGAAAGCCC CTAAGCTCCT GATCTACGAT GCATCCAATT TGGAAACAGG GGTCCCATCA
181 AGGTTTCAGTG GAAGTGGATC TGGGACAGAT TTTACTTTCA CCATCAGCGG CCTGCAGCCT
241 GAGGATATTG CAACATATTA CTGTCAACAG TATGATACTC TCCCTCTCAC TTTCGGCGGC
301 GGGACCAAGG TGGAGATCAA AC (SEQ ID NO: 28)
```

Amino Acid Sequence of Light Chain Variable Region

```
1 DIQMTQSPSS LSASVGDRVIT ITCQASQDIN NYLNWYQQKP GKAPKLLIYD ASNLETGVPS
61 RFSGSGSGTD FTFTISGLQP EDIATYYCQQ YDTLPLTFGG GTKVEIK (SEQ ID NO: 26)
```

FIGURE 13

ANTI-MUC18 ANTIBODY C6.1

Nucleotide Sequence of heavy chain variable region

```
1 CAGGTGCAGC TGGTGGAGTC GGGGGGAGGC GTGGTCCAGC CTGGGAGGTC CCTGAGACTC
61 TCCTGTGCAG CCTCTGGATT CACCTTCAGT AGCTATGCCA TGCACTGGGT CCGCCAGGCT
121 CCAGGCAAGG GGCTGGAGTG GGTGGCAGTT ATATCATATG ATGGAAGTAA TAAATACTAT
181 GCAGACTCCG TGAAGGGCCG ATTCACCATC TCCAGAGACA ATTCCAAGAA CACGCTGTAT
241 CTGCAAATGA ACAGCCTGAG AGCTGAGGAC ACGGCTGTGT ATTACTGTGC GAGATCGATT
301 TTTGGAGTGG TTATCGACTA CGGTATGGAC GTCTGGGGCC AAGGGACCAC GGTCAACGTC
361 TCCTCAG (SEQ ID NO: 31)
```

Amino Acid Sequence of Heavy Chain Variable Region

```
1 QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV ISYDGSNKYY
61 ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARSI FGVVIDYGMD VWGQGTTVTV
121 SS (SEQ ID NO: 29)
```

Nucleotide Sequence of light chain variable region

```
1 GACATCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CAGAGTCACC
61 ATCACTTGCC GGGCGAGTCA GGGCATTAGA AATTATTTAG CCTGGTATCA GCAGAATCCA
121 GGGAAAGTTC CTAAGCTCCT GATCTATGGT GCATCCACTT TGCAATCAGG GGTCCCATCT
181 CGGTTCAAGT GCAGTGGATC TGGGACAGAT TTTACTCTCA CCATCAGCAG CCTGCAGCCT
241 GAAGATGTTG CAACTTATTA CTGTCAAAG TTTAGCAGTC CCCCATTAC TTTTCGGCCCT
301 GGGACCAAAG TGGATATCAG TC (SEQ ID NO: 32)
```

Amino Acid Sequence of Light Chain Variable Region

```
1 DIQMTQSPSS LSASVGDRVT ITCRASQGIR NYLAWYQQNP GKVPKLLIYG ASTLQSGVPS
61 RFSGSGSGTD FTLTISSLQP EDVATYYCQK FSSPPFTFGP GTKVDIS (SEQ ID NO: 30)
```

FIGURE 14

ANTI-MUC18 ANTIBODY C6.9

Nucleotide Sequence of heavy chain variable region

```
1 CAGGTGCAGC TGGAGCAGTC GGGGCCAGGA CTGGTGAAGC CTCAGAGAC CCTGTCCCTC
61 ACCTGCACTG TCTCTGGTGG CTCCATCAGC AGTGGTACTT ACCACTGGAG CTGGATCCGC
121 CAGCACCCAG GGAGGGGCCT GGAGTGGATT GGATACATCT ATTACAGTGG GAGCACCTAC
181 CACAACCCGT CCCTCAAGAG TCGAATTACC ATATCAGTAG ACACGTCTAA GAACCAGTTC
241 TCCCTGAAGC TGAGCTCTGT GACGGCCGCG GACACGGCCG TGTATTACTG TGCGAGAGGG
301 GGAGATGGCT ACAGATACTG GGGCCAGGGA ACCCTGGTCA CCGTCTCCTC AG (SEQ ID
NO: 35)
```

Amino Acid Sequence of Heavy Chain Variable Region

```
1 QVQLEQSGPG LVKPSETLSL TCTVSGGSIS SGTYHWSWIR QHPGRGLEWI GYIYYSGSTY
61 HNP SLKSRIT ISVDTSKNQF SLKLSSVTAA DTA VYYCARG GDGYRYWGQG TLVTVSS (SEQ
ID NO: 33)
```

Nucleotide Sequence of light chain variable region

```
1 GAAATAGTGA TGACGCAGTC TCCAGCCACC CTGTCTGTGT CTCCAGGGGA AAGAGCCACC
61 CTCTCCTGCA GGGCCAGTCA GAGTATTAGC AACAACTTCG CCTGGTACCA GCAGAAACCT
121 GGCCAGGCTC CCAGGCTCCT CATCTTTGGT GCATCCACCA GGGCCACTGG TATCCCAGCC
181 AGGTT CAGTG GCAGTGGGTC TGGGACAGAA T TCACTCTCA CCATCAGCAG CCTACAGTCT
241 GAAGATTTTG CAGTTTATTA CTGTCAGCAG TATAATAACT GGCCTCGGAC GTTCGGCCAA
301 GGGACCAAGG TGGAAATCAA AC (SEQ ID NO: 36)
```

Amino Acid Sequence of Light Chain Variable Region

```
1 EIVMTQSPAT LSVSPGERAT LSCRASQ SIS NNFAWYQQKP GQAPRLLIFG ASTRATGIPA
61 RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ YNNWPRTFGQ GTKVEIK (SEQ ID NO: 34)
```

FIGURE 15

ANTI-MUC18 ANTIBODY C6.2

Nucleotide Sequence of heavy chain variable region

```
1 CAGGTGCAGC TGCAGGAGTC GGGCCCAGGA CTGGTGAAGC CCTCGGAGAC CCTGTCCCTC
61 ACCTGCACTG TCTCTGGTGG CTCCATCAGT ACTTACTACT GGAGTTGGAT CCGGCAGCCC
121 CCAGGGAAGG GACTGGAGTG GATTGGATAC ATCTATTACA CTGGGAACAC CTACTACAAC
181 CCCTCCCTCA AGAGTCGAGT CACCGTTTCA GTTGACACGT CCAAGAACCA GTTCTCCCTG
241 AAGCTGAACT CTGTGACCGC TCGGACACG GCCGTGTATT ACTGTGCGAG AGATCCAGGC
301 CAGTGGCTGG TCCCTGATGC TTTTGATATC TGGGGCCAAG GGACAATGGT CTCCGTCTCT
361 TCAG (SEQ ID NO: 39)
```

Amino Acid Sequence of Heavy Chain Variable Region

```
1 QVQLQESGPG LVKPSETLSL TCTVSGGSIS TYYWSWIRQP PGKGLEWIGY IYYTGNTYYN
61 PSLKSRVTVS VDTSKNQFSL KLNSVTAADT AVYYCARDPG QWLVPDAFDI WGQGTMSVSV
121 S (SEQ ID NO: 37)
```

Nucleotide Sequence of light chain variable region

```
1 GATATTGTGA TGA CT CAGTC TCCACTCTCC CTGCCCCGTCA TTCCTGGAGA GCCGGCCTCC
61 ATCTCCTGCA GGTCTAGTCA GAGCCTCCTG CAGAGTAATG GAAACAAC TA TTTGGATTGG
121 TACCTGCAGA AGCCAGGGCA GTCTCCACAG CTCCTGATCT ATTTGGGTTC TAATCGGGCC
181 TCCGGGGTCC CTGACAGGTT CAGTGGCAGT GGATCAGGCA CAGATTTTAC ACTGAAAATC
241 AGCAGAGTGG AGGCTGACGA TGT TGGGATT TATTACTGCA TGCAAGCTCT CCAAATTCCT
301 CTCAC TTTCG GCGGAGGGAC CAAGGTGGAG ATCAAAC (SEQ ID NO: 40)
```

Amino Acid Sequence of Light Chain Variable Region

```
1 DIVMTQSPLS LPVIPGEPAS ISCRSSQSLL QSNNGNYYLDW YLQKPGQSPQ LLIYLGSNRA
61 SGVPDRFSGS GSGTDFTLKI SRVEADDVGI YYCMQALQIP LTFGGGTKVE IK (SEQ ID
NO: 38)
```

FIGURE 16

								Section 1	
	(1)	1	10	20	30	40	53		
A15-3.10_HC	(1)	QVQLQESGGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYY							
VH4-59	(1)	QVQLQESGGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYY							
Consensus	(1)	QVQLQESGGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYY							
								Section 2	
	(54)	54	60	70	80	90	106		
A15-3.10_HC	(54)	STNYNPSLKSRVTISVDTSKNQPSLRLLSSVTAADTALYYCARDQGQWLLPD							
VH4-59	(54)	SGSTNYNPSLKSRVTISVDTSKNQPSLRLLSSVTAADTALYYCAR-----							
Consensus	(54)	S STNYNPSLKSRVTISVDTSKNQPSLRLLSSVTAADTALYYCAR							
								Section 3	
	(107)	107	121						
A15-3.10_HC	(107)	AFDIWGQGTMTVSS							
VH4-59	(98)	-----							
Consensus	(107)								

positives: 79.3% identity: 75.0%

Appl. No.: Not Assigned Atty Docket: ABGENIX.030C1

Section 1

	(1)	1	10	20	30	40	53
A15-3.10_LC	(1)	DIQMTQSPSSITLASVGDRTITCRASQIS YLNWYQKPKAPKLLIYAASS					
O2	(1)	DIQMTQSPSSITLASVGDRTITCRASQIS YLNWYQKPKAPKLLIYAASS					
Consensus	(1)	DIQMTQSPSSITLASVGDRTITCRASQIS YLNWYQKPKAPKLLIYAASS					

Section 2

	(54)	54	60	70	80	90	106
A15-3.10_LC	(54)	LQSGVPSRFRSGSGSDTFTLTISSLQPEDFATYYCQSYSTPECSFGQGTKL					
O2	(54)	LQSGVPSRFRSGSGSDTFTLTISSLQPEDFATYYCQSYSTPECSFGQGTKL					
Consensus	(54)	LQSGVPSRFRSGSGSDTFTLTISSLQPEDFATYYC QSYSTP					

Section 3

	(107)	107
A15-3.10_LC	(107)	EIK
O2	(96)	---
Consensus	(107)	

positives: 85.3%	identity: 84.4%
------------------	-----------------

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli et al.

Appl. No.: Not Assigned Atty Docket: ABGENIX.030CI

FIGURE 18

								Section 1	
	(1)	1	10	20	30	40	53		
A15-3.22 HC	(1)	QVQIQESGPGGVKPSQTLSTCTVSGGSISSGGYYWIRQHPGKGLEWIGFI							
VH4-31	(1)	QVQIQESGPGGVKPSQTLSTCTVSGGSISSGGYYWIRQHPGKGLEWIGFI							
Consensus	(1)	QVQIQESGPGGVKPSQTLSTCTVSGGSISSGGYYWIRQHPGKGLEWIGFI							
								Section 2	
	(54)	54	60	70	80	90	106		
A15-3.22 HC	(54)	YYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAR						EGDGFDFY	
VH4-31	(54)	YYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAR						-----	
Consensus	(54)	YYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAR							
								Section 3	
	(107)	107	117						
A15-3.22 HC	(107)	WGQGTIVTVSS							
VH4-31	(100)	-----							
Consensus	(107)								

Positives: 84.6% Identity: 82.9%

FIGURE 19

										Section 1	
		(1)	1	10	20	30	40	50	53		
A15-322_LC	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGIKNDLGWYQOKPGKAPKRLIYAASS									
A30	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGIKNDLGWYQOKPGKAPKRLIYAASS									
Consensus	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGIKNDLGWYQOKPGKAPKRLIYAASS									
										Section 2	
		(54)	54	60	70	80	90	100	106		
A15-322_LC	(54)	LQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLOHNSYP-----									
A30	(54)	LQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLOHNSYP-----									
Consensus	(54)	LQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLOHNSYP									
										Section 3	
		(107)	107								
A15-322_LC	(107)	K									
A30	(96)	-									
Consensus	(107)										

Positives: 88.8% Identity: 88.8%

Appl. No.: Not Assigned Atty Docket: ABGENIX.030C1

		Section 1					
	(1)	1	10	20	30	40	53
A15-3.27_HC	(1)	QVQLQESGGPGLVKPSETLSLTCTVSGGSISYYWBIWIRQPPGKGLEWIGYIYY					
VH4-59	(1)	QVQLQESGGPGLVKPSETLSLTCTVSGGSISYYWBIWIRQPPGKGLEWIGYIYY					
Consensus	(1)	QVQLQESGGPGLVKPSETLSLTCTVSGGSISYYWBIWIRQPPGKGLEWIGYIYY					
		Section 2					
	(54)	54	60	70	80	90	106
A15-3.27_HC	(54)	EWTSINYNP SLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAR					DQGQWLLPD
VH4-59	(54)	SGTSINYNP SLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAR					-----
Consensus	(54)	S SSNYPNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAR					
		Section 3					
	(107)	107	121				
A15-3.27_HC	(107)	AFDIWGQGTMTVTS					
VH4-59	(98)	-----					
Consensus	(107)						

positives: 79.3%	identity: 76.0%
------------------	-----------------

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli et al.

Appl. No.: Not Assigned Atty Docket: ABGENIX.030C1

FIGURE 21

Section 1								
	(1)	1	10	20	30	40	53	
A15-3.27_LC	(1)	DIQMTQSEPSLSASVGDRVTITCRASQGI RNDLGWYQQKPGKAPKRLIYAASS						
A30	(1)	DIQMTQSEPSLSASVGDRVTITCRASQGI RNDLGWYQQKPGKAPKRLIYAASS						
Consensus	(1)	DIQMTQSEPSLSASVGDRVTITCRASQGI RNDLGWYQQKPGKAPKRLIYAASS						
Section 2								
	(54)	54	60	70	80	90	106	
A15-3.27_LC	(54)	LQSGVPSRFSGSGCTETFTLTISLQPEDFATYYCLQHNSYPWTFGOGTKVEI						
A30	(54)	LQSGVPSRFSGSGCTETFTLTISLQPEDFATYYCLQHNSYP-----						
Consensus	(54)	LQSGVPSRFSGSGCTETFTLTISLQPEDFATYYCLQHNSYP						
Section 3								
	(107)	107						
A15-3.27_LC	(107)	K						
A30	(96)	-						
Consensus	(107)							

Positives: 88.8% Identity: 69.8%

FIGURE 23

								Section 1	
	(1)	1	10	20	30	40	53		
A15-345_LC	(1)	DIVMTQSPDLSAVSLGERATTICKSSQSILYSSNNRNYLGWYQQRPGQPPKLL							
B3	(1)	DIVMTQSPDLSAVSLGERATTICKSSQSILYSSNNRNYLGWYQQRPGQPPKLL							
Consensus	(1)	DIVMTQSPDLSAVSLGERATTICKSSQSILYSSNNRNYLGWYQQRPGQPPKLL							
								Section 2	
	(54)	54	60	70	80	90	106		
A15-345_LC	(54)	IYWASTRESGVDPARTFSGSGSGTDFTLTINSISQAEDVAVYYCQYYSTERSFGQ							
B3	(54)	IYWASTRESGVDPARTFSGSGSGTDFTLTINSISQAEDVAVYYCQYYSTERSFGQ							
Consensus	(54)	IYWASTRESGVDPARTFSGSGSGTDFTLTINSISQAEDVAVYYCQYYSTERSFGQ							
								Section 3	
	(107)	107	113						
A15-345_LC	(107)	GTMVEIK							
B3	(102)	-----							
Consensus	(107)	GTMVEIK							

Positives: 86.7% Identity: 85.0%

FIGURE 24

Section 1									
	(1)	1	10	20	30	40	50	60	53
A15-3.65_HC	(1)	QVQLQESGGPGLVKPSQTLSTCTVSGGSIINSGGCIYWSWIRQHPGKGLEWIGYI							
VH4-31	(1)	QVQLQESGGPGLVKPSQTLSTCTVSGGSIINSGGCIYWSWIRQHPGKGLEWIGYI							
Consensus	(1)	QVQLQESGGPGLVKPSQTLSTCTVSGGSI SGG YWSWIRQHPGKGLEWIGYI							
Section 2									
	(54)	54	60	70	80	90	100	110	106
A15-3.65_HC	(54)	YSSGSTYYNPSLKSRITTSVDTSKNQFSIKLNSMTAADTAVYYCARDRETAGF							
VH4-31	(54)	YSSGSTYYNPSLKSRITTSVDTSKNQFSIKLNSMTAADTAVYYCAR-----							
Consensus	(54)	Y SSGSTYYNPSLKSRITTSVDTSKNQFSIKL SMTAADTAVYYCAR							
Section 3									
	(107)	107	110	115	120	125	130	135	119
A15-3.65_HC	(107)	DYWGQGTIVTVSS							
VH4-31	(100)	-----							
Consensus	(107)								

Positives: 79.8% Identity: 77.6%

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli et al.

Appl. No.: Not Assigned Atty Docket: ABGENIX.030C1

FIGURE 25

						Section 1
	(1)	10	20	30	40	53
A15-365_LC	(1)	DIQMTQSPSSLSASVGDRVTITCQASQDI NYLNWYQQKPGKAPKLLIYDASN				
08	(1)	DIQMTQSPSSLSASVGDRVTITCQASQDI NYLNWYQQKPGKAPKLLIYDASN				
Consensus	(1)	DIQMTQSPSSLSASVGDRVTITCQASQDI NYLNWYQQKPGKAPKLLIYDASN				
						Section 2
	(54)	54	60	70	80	90
A15-365_LC	(54)	LETGVPSRFSGSGSGTDFTFTIS LQPEDIAATYYCCQYD LP				
08	(54)	LETGVPSRFSGSGSGTDFTFTIS LQPEDIAATYYCCQYD LP				
Consensus	(54)	LETGVPSRFSGSGSGTDFTFTIS LQPEDIAATYYCCQYD LP				
						Section 3
	(107)	107				
A15-365_LC	(107)	K				
08	(96)	-				
Consensus	(107)					

Positives: 86.0% Identity: 86.0%

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli et al.

Appl. No.: Not Assigned Atty Docket: ABGENIX.030C1

FIGURE 26

								Section 1
	(1)	1	10	20	30	40	53	
A15-6.1 HC	(1)	QVQLVESGGGVVQPGKSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAIVSY						
VH3-30	(1)	QVQLVESGGGVVQPGKSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAIVSY						
Consensus	(1)	QVQLVESGGGVVQPGKSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAIVSY						
								Section 2
	(54)	54	60	70	80	90	106	
A15-6.1 HC	(54)	DGSNKYYADSVKGRFTISRDNKNTLYLQMNSIPAEEDTAVYYCARSIFGVVID						
VH3-30	(54)	DGSNKYYADSVKGRFTISRDNKNTLYLQMNSIPAEEDTAVYYCAR-----						
Consensus	(54)	DGSNKYYADSVKGRFTISRDNKNTLYLQMNSIPAEEDTAVYYCAR						
								Section 3
	(107)	107	122					
A15-6.1 HC	(107)	YGMDVWGQGTTVTVSS						
VH3-30	(99)	-----						
Consensus	(107)							

positives: 80.3% Identity: 79.5%

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli et al.

Appl. No.: Not Assigned Atty Docket: ABGENIX.030C1

FIGURE 27

Section 1									
	(1)	1	10	20	30	40	54		
A15-6.1_LC	(1)	DIQMTQSPSSLSASVGDRTITTCRASQGI RNYLAWYQQNPGKVPKLLIYAASTL							
A20	(1)	DIQMTQSPSSLSASVGDRTITTCRASQGI RNYLAWYQQNPGKVPKLLIYAASTL							
Consensus	(1)	DIQMTQSPSSLSASVGDRTITTCRASQGI NYLAWYQQ PGKVPKLLIYAASTL							
Section 2									
	(55)	55	60	70	80	90	107		
A15-6.1_LC	(55)	QSGVPSRFSGSGSGTDFTLTISSTLOPEDVATYYCQKF SPPFTFGPGTKVDIS							
A20	(55)	QSGVPSRFSGSGSGTDFTLTISSTLOPEDVATYYCQKF NSAP-----							
Consensus	(55)	QSGVPSRFSGSGSGTDFTLTISSTLOPEDVATYYCQKF S P							

Positives: 85.0% Identity: 83.2%

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli et al.

Appl. No.: Not Assigned Atty Docket: ABGENIX.030C1

FIGURE 28

Section 1									
	(1)	1	10	20	30	40	50	60	53
A15-6.12_HC	(1)	QVQLLEQSGPGLVKPSSETLSLTCTVSGGSISSGTYHWSWIRQHPGKGLIEWIGYI							
VH4-31	(1)	QVQLLEQSGPGLVKPSSETLSLTCTVSGGSISSGTYHWSWIRQHPGKGLIEWIGYI							
Consensus	(1)	QVQL SGPGLVKPS TSLTCTVSGGSISSG YHWSWIRQHPGKGLIEWIGYI							
Section 2									
	(54)	54	60	70	80	90	100	110	106
A15-6.12_HC	(54)	YYSGSTYHNPSLKSRITISVDTSKNQFSLKLSSVTAADTAVYYCARGGDGYRY							
VH4-31	(54)	YYSGSTYHNPSLKSRITISVDTSKNQFSLKLSSVTAADTAVYYCAR-----							
Consensus	(54)	YYSGSTYHNPSLKSRITISVDTSKNQFSLKLSSVTAADTAVYYCAR							
Section 3									
	(107)	107	117						
A15-6.12_HC	(107)	WGQGTLLVTVSS							
VH4-31	(100)	-----							
Consensus	(107)								

positives: 81.2% identity: 77.6%

Appl. No.: Not Assigned Atty Docket: ABGENIX.030CI

FIGURE 29

										Section 1
		(1)	1	10	20	30	40	50	59	
A15-6.12_LC	L2	(1)	EIVMTQSPATLSVSPGERATLSCRASQSIISNLA							AWYQOKPGQAPRLILFGAST
	(1)	EIVMTQSPATLSVSPGERATLSCRASQSIISNLA							AWYQOKPGQAPRLILFGAST	
	(1)	EIVMTQSPATLSVSPGERATLSCRASQSIISNLA							AWYQOKPGQAPRLILFGAST	
Consensus		(1)	EIVMTQSPATLSVSPGERATLSCRASQSIISNLA							AWYQOKPGQAPRLILFGAST
										Section 2
		(54)	54	60	70	80	90	100	106	
A15-6.12_LC	L2	(54)	RATGTPARFSGSGSGTEFTLTITISSLQSEDAVYYCQOYNWNP							-----
	(54)	RATGTPARFSGSGSGTEFTLTITISSLQSEDAVYYCQOYNWNP							RTFGQGTKVEI	
	(54)	RATGTPARFSGSGSGTEFTLTITISSLQSEDAVYYCQOYNWNP								
Consensus		(54)	RATGTPARFSGSGSGTEFTLTITISSLQSEDAVYYCQOYNWNP							
										Section 3
		(107)	107	116	125	134	143	152	161	
A15-6.12_LC	L2	(96)	K							
	(107)	K								
	(107)	K								
Consensus		(107)	K							

positives: 86.9%	identity: 85.0%
------------------	-----------------

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli et al.

Appl. No.: Not Assigned Atty Docket: ABGENIX.030C1

FIGURE 30

Section 1							
	(1)	1	10	20	30	40	53
A15-6.2 HC	(1)	QVQLQESGGPGLVKPSETLSITCTVSGGGSTSYYSWIRQPPGKGLEWIGYIYY					
VH4-59	(1)	QVQLQESGGPGLVKPSETLSITCTVSGGGSTSYYSWIRQPPGKGLEWIGYIYY					
Consensus	(1)	QVQLQESGGPGLVKPSETLSITCTVSGGGSTSYYSWIRQPPGKGLEWIGYIYY					
Section 2							
	(54)	54	60	70	80	90	106
A15-6.2 HC	(54)	TGNTYYNPSLKSRTISVDTSKNQPSLKL SVTAADTAVYYCARDPGQWLVPD					
VH4-59	(54)	EGSTYNPSLKSRTISVDTSKNQPSLKL SVTAADTAVYYCAR-----					
Consensus	(54)	SG T YNPSLKSRTISVDTSKNQPSLKL SVTAADTAVYYCAR					
Section 3							
	(107)	107	121				
A15-6.2 HC	(107)	AFDIWGQGTMOVSVSS					
VH4-59	(98)	-----					
Consensus	(107)						

positives: 77.7% identity: 75.2%

Bar-Eli et al.

FIGURE 31

Section 1

	(1)	10	20	30	40	54
A15-6.2 LC	(1)	DI VMTQSPHS L P V T G G E P A S I S C R S S Q S L L T Q S N G N N Y L D N Y L Q K P G Q S P Q L L I Y				
A19	(1)	DI VMTQSPHS L E W T G G E P A S I S C R S S Q S L I H S N G N Y L D N Y L Q K P G Q S P Q L L I Y				
Consensus	(1)	DI VMTQSPHS L P V T G G E P A S I S C R S S Q S L L S N G N Y L D W Y L Q K P G Q S P Q L L I Y				

Section 2

	(55)	55	60	70	80	90	108
A15-6.2 LC	(55)	L G S N R A S G V P D R F S G S G S G T D F T L K I S R V E A D D V G I Y Y C M Q A L Q T P L T F G G G T K					
A19	(55)	L G S N R A S G V P D R F S G S G S G T D F T L K I S R V E A D D V G M Y Y C M Q A L Q T P L T F G G G T K					
Consensus	(55)	L G S N R A S G V P D R F S G S G S G T D F T L K I S R V E A D D V G I Y Y C M Q A L Q P					

Section 3

	(109)	109	112
A15-6.2 LC	(109)	V E I K	
A19	(101)	----	
Consensus	(109)		

positives: 85.7% identity: 83.9%

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli et al.

Appl. No.: Not Assigned Atty Docket: ABGENIX.030C1

FIGURE 32

										Section 1
	(1)	1	10	20	30	40	53			
A15-6.9_HC	(1)	QVQLTQSGPGLVLRPEITLTLCTVSGGSISSGTYHWSWIRQHPGKGLEWIGYI								
VH4-31	(1)	QVQLTQSGPGLVLRPEITLTLCTVSGGSISSGTYHWSWIRQHPGKGLEWIGYI								
Consensus	(1)	QVQL TSGPGLVKPS TLSLTCTVSGGSISG YHWSWIRQHFGKLEWIGYI								
										Section 2
	(54)	54	60	70	80	90	106			
A15-6.9_HC	(54)	YYSGSTYHNP SLKSRITISVDTSKNQFSLKLSSVTAADTAVYYCARGGDGYRY								
VH4-31	(54)	YYSGSTYHNP SLKSRITISVDTSKNQFSLKLSSVTAADTAVYYCAR-----								
Consensus	(54)	YYSGSTYHNP SLKSRITISVDTSKNQFSLKLSSVTAADTAVYYCAR								
										Section 3
	(107)	107	117							
A15-6.9_HC	(107)	WGQGTLVTVSS								
VH4-31	(100)	-----								
Consensus	(107)									

positives: 61.2% identity: 77.8%

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli et al.

Appl. No.: Not Assigned Atty Docket: ABGENIX.030C1

FIGURE 33

Section 1									
	(1)	1	10	20	30	40	54		
A15-6.9_LC	(1)	EIVMTQSPATLSVSPGERATLSCRASQSSNNFAWYQOKPGQAPRLILFGASTR							
L2	(1)	EIVMTQSPATLSVSPGERATLSCRASQSSNNLAWYQOKPGQAPRLILFGASTR							
Consensus	(1)	EIVMTQSPATLSVSPGERATLSCRASQSS N AWYQOKPGQAPRLILFGASTR							
Section 2									
	(55)	55	60	70	80	90	107		
A15-6.9_LC	(55)	ATGIPARFSGSGSGTEFTLTISSLQSEDAVYYCQYNNWERTFGQGTKVEIK							
L2	(55)	ATGIPARFSGSGSGTEFTLTISSLQSEDAVYYCQYNNW-----							
Consensus	(55)	ATGIPARFSGSGSGTEFTLTISSLQSEDAVYYCQYNNWF							

positives: 86.9% identity: 85.0%

Bar-Eli et al.

FIGURE 34

Section 2							
	(1)	10	20	30	40	53	
A15-6.11_HC	(1)	QVQLQESGGPGLVKPSTLTCTVSGGSISGGTYHWSWIRQHPGKGLEWIGY					
VH4-31	(1)	QVQLQESGGPGLVKPSTLTCTVSGGSISGGTYHWSWIRQHPGKGLEWIGYI					
Consensus	(1)	QVQLQESGGPGLVKPSTLTCTVSGGSISGG YHWSWIRQHPGKGLEWIGYI					
Section 3							
	(54)	54	60	70	80	90	106
A15-6.11_HC	(54)	YYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGDGYKY					
VH4-31	(54)	YYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAR					-----
Consensus	(54)	YYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAR					
Section 4							
	(107)	107	117				
A15-6.11_HC	(107)	WGQGTIVTVSS					
VH4-31	(100)	-----					
Consensus	(107)						

positives: 83.8%	identity: 82.9%
------------------	-----------------

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli et al.

Appl. No.: Not Assigned Atty Docket: ABGENIX.030C1

FIGURE 35

		Section 1					
	(1)	1	10	20	30	40	53
A15-6.11_LC	(1)	EIVMTQSPATLSVSPGERATLSCRAQSQSVSNLAWYQOKPGCAPRLITYGAST					
L2	(1)	EIVMTQSPATLSVSPGERATLSCRAQSQSVSNLAWYQOKPGCAPRLITYGAST					
Consensus	(1)	EIVMTQSPATLSVSPGERATLSCRAQSQSVSNLAWYQOKPGCAPRLITYGAST					
		Section 2					
	(54)	54	60	70	80	90	106
A15-6.11_LC	(54)	RATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQYNNWPERTFGQGTKVEI					
L2	(54)	RATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQYNNWPERTFGQGTKVEI					
Consensus	(54)	RATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQYNNWPERTFGQGTKVEI					
		Section 3					
	(107)	107					
A15-6.11_LC	(107)	K					
L2	(96)	-					
Consensus	(107)						

positives: 87.9% identity: 87.9%

FIGURE 36

CLONE #	VH	#DEL	VH END	#N's	N Sequence	DH	Size of D	D Sequence	#N's	N Sequence	JH	#del	JH Segment
A15-3.10	DP-714-59	0	GAGAGA	8	TCAGGGGC	D21-9	8	AGTGGGTTA	7	CTACCCG	JH3B	0	ATGCTT
A15-3.22	DP-654-31	0	GAGAGA	9	GGGAGATGG	-	-	-	-	-	JH4B	-4	CTTTGA
A15-3.27	DP-714-59	0	GAGAGA	8	TCAGGGGC	D21-9	8	AGTGGGTTA	7	CTACCCG	JH3B	0	ATGCTT
A15-3.45	DP-141-18	0	GAGAGA	6	AAGTAA	D3-10	12	GGTTCGGGGAGT	2	CC	JH3B	-9	ACTACT
A15-3.65	DP-654-31	0	GAGAGA	8	TCGGGAAA	D6-13	8	CAGCTGGT	4	TTTT	JH5A	-11	GACTAC
A15-6.1	DP-493-30	3	GCGAGA	1	T	D3-3	18	CGATTTTGGAGTGGTTA	3	TCG	JH6B	-12	ACTACG
A15-6.2	DP-714-59	0	GAGAGA	7	TCCAGGC	D6-19	11	CAGTGGCTGGT	5	CCCTG	JH3B	0	ATGCTT
A15-6.9	DP-654-31	1	CGAGAG	3	GGG	D5-24	11	GAGATGGCTAC	4	AGAT	JH1	-16	ACTGGG
A15-6.11	DP-654-31	1	CGAGAG	3	GGG	D5-24	13	GAGATGGCTACAA	2	GT	JH1	-16	ACTGGG
A15-6.12	DP-654-31	1	CGAGAG	3	GGG	D5-24	11	GAGATGGCTAC	4	AGAT	JH1	-16	ACTGGG

CLONE	vk	#del	vk end	#n	N SEQ	JK	#del	JK end
A15-3.10	02/012DPK	0	CCCTCC	9	GGAGTGCAG	JK2	-7	TTTTGG
A15-3.22	A30	3	TTACCC	0	0	JK4	0	GCTCAC
A15-3.27	A30	3	TTACCC	0	0	JK1	0	GTGGAC
A15-3.45	B3/DPK24	1	TCCCTC	3	GGT	JK1	-5	CGTTCG
A15-3.65	08/018DPK	1	TCCCTC	0	0	JK4	-2	TCACTTTC
A15-6.1	A20/DPK4	3	GTCCCC	0	0	JK3	0	ATTAC
A15-6.2	A3A19DPK	1	TCCCTC	0	0	JK4	-2	TCACTTTC
A15-6.9	L2/DPK21	1	GGCCTC	0	0	JK1	-2	GGACGT
A15-6.11	L2/DPK21	1	GGCCTC	0	0	JK1	-2	GGACGT
A15-6.12	L2/DPK21	1	GGCCTC	0	0	JK1	-2	GGACGT